title: Comparison of two dialysers (AN69ST vs. FX100) for heparin-free dialysis in patients with oral anticoagulation.
abstract: BACKGROUND
  Heparin-free dialysis (HFD), i.e. only priming of the dialyser and no systemic heparinization, might reduce the risk of bleeding in dialysis patients receiving oral anticoagulation. The efficacy of HFD with two different membranes [polyacrylonitrile (AN69ST) vs. polysulphone (FX100)] was therefore investigated.
  
  
  METHODS
  In a crossover design, 10 patients were treated with either membrane for 1 week (total 30 sessions). Weekly Kt/V and urea reduction rate (URR) were measured and thrombus formation evaluated by measurement of D-dimer and inspection of the air traps and dialyser.
  
  
  RESULTS
  Change of clotting markers was similar with both membranes. Complete thrombosis occurred in 3/30 patients with the AN69ST and in 1/30 patients with the FX100 membrane. Kt/V did not differ between the groups, but the URR was slightly higher with the FX100.
  
  
  CONCLUSIONS
  HFD prevents dialyser occlusion in the majority of patients treated with oral anticoagulants. Both polysulphone and polyacrylonitrile membranes seem to be equally effective.
authors.affiliation: Department of Internal Medicine III, Division of Nephrology and Dialysis, University Hospital, Vienna, Austria.
authors.forename: Katharina
authors.initials: K
authors.lastname: Kodras
authors.forename: Thomas
authors.initials: T
authors.lastname: Benesch
authors.forename: Irmgard
authors.initials: I
authors.lastname: Neumann
authors.forename: Martin
authors.initials: M
authors.lastname: Haas
mesh_terms: D000180:Acrylic Resins; D000284:Administration, Oral; D000327:Adsorption; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D001672:Biocompatible Materials; D018592:Cross-Over Studies; D004867:Equipment Design; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D019934:International Normalized Ratio; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010644:Phenprocoumon / Q000008:administration & dosage* / Q000009:adverse effects; D011108:Polymers; D011446:Prospective Studies; D006435:Renal Dialysis / Q000295:instrumentation*; D013450:Sulfones; D013927:Thrombosis / Q000097:blood / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D014508:Urea / Q000097:blood
chemical_list: D000180:Acrylic Resins; D000925:Anticoagulants; D001672:Biocompatible Materials; D005338:Fibrin Fibrinogen Degradation Products; D008567:Membranes, Artificial; D011108:Polymers; D013450:Sulfones; C036309:fibrin fragment D; C010504:polyacrylonitrile; C017662:polysulfone P 1700; D014508:Urea; D006493:Heparin; D010644:Phenprocoumon